Despite the high efficacy of everolimus for treating HR-positive advanced breast cancer, it can result in serious adverse effects, including interstitial pneumonia, infections, stomatitis, delayed wound healing, and hyperglycemia, because mTOR inhibition suppresses basic cellular processes. This evidence concerns the gene MTOR and breast carcinoma.